NDURE

What this means for you

This application is over — abandoned 06 Aug 2024. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number

79379393

Mark type

Stylized text

Filed

19 Apr 2023

Abandoned

06 Aug 2024

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations; biological preparations for medical purposes; diagnostic preparations and materials; therapeutic preparations and substances; anti-angiogenesis preparations; anti-cancer preparations; anti-inflammatory preparations; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, physiological disorders, hormonal disorders, inherited disease, single gene disorders, respiratory diseases, gastro-intestinal disorders, circulatory disorders, dermatological conditions, immuno-deficiencies, organ damage, cell proliferation, peripheral neurological disorders, genitourinary disorders, musculoskeletal disorders, and blood disorders; diagnostic reagents for medical use; DNA, antibodies and proteins for medical use; DNA and/or antibodies and/or proteins that stimulate cells for medical use; DNA, antibodies and proteins for therapeutic use; diagnostic products and reagents for medical use
• Class 042 — Scientific and technological services: Medical and pharmacological research services; scientific and technological services and research and design relating thereto; scientific research for medical purposes; pharmaceutical research and development services; pharmaceutical testing; research and development in the biotechnology field; research and development services in the field of antibodies; biotechnology services; conducting clinical trials; biological research, clinical research and medical research; providing information about the results of clinical trials for pharmaceutical products; analytic and diagnostic research and laboratory services in the field of science; development of assays, both for products and analysis, provided for others; laboratory services; research and development of new products for others; research and scientific analysis relating to drug discovery, as well as development thereof for others; scientific advisory services; scientific consultancy; scientific research and development; scientific research in the field of biotechnology and pharmaceuticals; management of scientific research projects; issuing of scientific information; advisory services relating to scientific and clinical research; provision of information and consultancy in relation to the aforesaid services

Owner

• Elasmogen Ltd, GB

Prosecution history

• 20 Jun 2025 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
• 08 Apr 2025 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
• 08 Apr 2025 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
• 19 Aug 2024 — ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
• 19 Aug 2024 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
• 27 Feb 2024 — REFUSAL PROCESSED BY IB
• 05 Feb 2024 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
• 05 Feb 2024 — REFUSAL PROCESSED BY MPU
• 19 Jan 2024 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
• 18 Jan 2024 — NON-FINAL ACTION WRITTEN
• 18 Jan 2024 — NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
• 18 Jan 2024 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
• 17 Jan 2024 — NON-FINAL ACTION WRITTEN
• 17 Jan 2024 — ASSIGNED TO EXAMINER
• 02 Jan 2024 — CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED